The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53
Open accessAbstract
Increased transcription of ribosomal RNA genes (rDNA) by RNA Polymerase I is a common feature of human cancer, but whether it is required for the malignant phenotype remains unclear. We show that rDNA transcription can be therapeutically targeted with the small molecule CX-5461 to selectively kill B-lymphoma cells in vivo while maintaining a viable wild-type B cell population. The therapeutic effect is a consequence of nucleolar disruption and activation of p53-dependent apoptotic signaling. Human leukemia and lymphoma cell lines also show high sensitivity to inhibition of rDNA transcription that is dependent on p53 mutational status. These results identify selective inhibition of rDNA transcription as a therapeutic strategy for the cancer specific activation of p53 and treatment of hematologic malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice
Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., & Brinster, R. L. (1985) · Nature · doi:10.1038/318533a0 · Cited by 1,779
Boisvert, F.-M., van Koningsbruggen, S., Navascués, J., & Lamond, A. I. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2184 · Cited by 1,619
Dang, C. V., O’Donnell, K. A., Zeller, K. I., Nguyen, T., Osthus, R. C., & Li, F. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.07.014 · Cited by 1,188
Boulon, S., Westman, B. J., Hutten, S., Boisvert, F.-M., & Lamond, A. I. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.024 · Cited by 1,103
MYC as a regulator of ribosome biogenesis and protein synthesis
van Riggelen, J., Yetil, A., & Felsher, D. W. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2819 · Cited by 956
Does the ribosome translate cancer?
Ruggero, D., & Pandolfi, P. P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1015 · Cited by 928
Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis
Eischen, C. M., Weber, J. D., Roussel, M. F., Sherr, C. J., & Cleveland, J. L. (1999) · Genes & Development · doi:10.1101/gad.13.20.2658 · Cited by 819
Systematic Identification of Pathways That Couple Cell Growth and Division in Yeast
Jorgensen, P., Nishikawa, J. L., Breitkreutz, B.-J., & Tyers, M. (2002) · Science · doi:10.1126/science.1070850 · Cited by 768
c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I
Grandori, C., Gomez-Roman, N., Felton-Edkins, Z. A., Ngouenet, C., Galloway, D. A., Eisenman, R. N., & White, R. J. (2005) · Nature Cell Biology · doi:10.1038/ncb1224 · Cited by 665
Regulation of HDM2 activity by the ribosomal protein L11
Lohrum, M. A. E., Ludwig, R. L., Kubbutat, M. H. G., Hanlon, M., & Vousden, K. H. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00134-x · Cited by 623
Cited by
Regulation and metabolic functions of mTORC1 and mTORC2
Szwed, A., Kim, E., & Jacinto, E. (2021) · Physiological Reviews · doi:10.1152/physrev.00026.2020 · Cited by 813
Ribosome biogenesis in cancer: new players and therapeutic avenues
Pelletier, J., Thomas, G., & Volarević, S. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.104 · Cited by 812
Targeting the translation machinery in cancer
Bhat, M., Robichaud, N., Hulea, L., Sonenberg, N., Pelletier, J., & Topisirovic, I. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4505 · Cited by 799
Ribosomal proteins: functions beyond the ribosome
Zhou, X., Liao, W.-J., Liao, J.-M., Liao, P., & Lu, H. (2015) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjv014 · Cited by 743
An overview of pre‐ribosomal RNA processing in eukaryotes
Henras, A. K., Plisson‐Chastang, C., O'Donohue, M., Chakraborty, A., & Gleizes, P. (2015) · WIREs RNA · doi:10.1002/wrna.1269 · Cited by 594
CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours
Xu, H., Di Antonio, M., McKinney, S., Mathew, V., Ho, B., O’Neil, N. J., Santos, N. D., Silvester, J., Wei, V., Garcia, J., et al. (2017) · Nature Communications · doi:10.1038/ncomms14432 · Cited by 580
G-quadruplexes: a promising target for cancer therapy
Kosiol, N., Juranek, S., Brossart, P., Heine, A., & Paeschke, K. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01328-4 · Cited by 533
Ribosome Levels Selectively Regulate Translation and Lineage Commitment in Human Hematopoiesis
Khajuria, R. K., Munschauer, M., Ulirsch, J. C., Fiorini, C., Ludwig, L. S., McFarland, S. K., Abdulhay, N. J., Specht, H., Keshishian, H., Mani, D. R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.036 · Cited by 416
“(H) Western blot detection of the indicated proteins from lysates of differentiating HSPCs at 72 hr after treatment with increasing concentrations of CX-5461.”
MethodInfluentialRibosomal proteins and human diseases: molecular mechanisms and targeted therapy
Kang, J., Brajanovski, N., Chan, K. T., Xuan, J., Pearson, R. B., & Sanij, E. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00728-8 · Cited by 408
Self-citationSharma, S., Langhendries, J.-L., Watzinger, P., Kötter, P., Entian, K.-D., & Lafontaine, D. L. J. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv075 · Cited by 392
New frontiers in translational control of the cancer genome
Truitt, M. L., & Ruggero, D. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.27 · Cited by 378
The cell proliferation antigen Ki-67 organises heterochromatin
Sobecki, M., Mrouj, K., Camasses, A., Parisis, N., Nicolas, E., Llères, D., Gerbe, F., Prieto, S., Krasinska, L., David, A., et al. (2016) · eLife · doi:10.7554/elife.13722 · Cited by 362
Marcel, V., Ghayad, S. E., Belin, S., Therizols, G., Morel, A.-P., Solano-Gonzàlez, E., Vendrell, J. A., Hacot, S., Mertani, H. C., Albaret, M. A., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.013 · Cited by 358
Increased global transcription activity as a mechanism of replication stress in cancer
Kotsantis, P., Silva, L. M., Irmscher, S., Jones, R. M., Folkes, L., Gromak, N., & Petermann, E. (2016) · Nature Communications · doi:10.1038/ncomms13087 · Cited by 336
A Targeting Modality for Destruction of RNA Polymerase I that Possesses Anticancer Activity
Peltonen, K., Colis, L., Liu, H., Trivedi, R., Moubarek, M. S., Moore, H. M., Bai, B., Rudek, M. A., Bieberich, C. J., & Laiho, M. (2014) · Cancer Cell · doi:10.1016/j.ccr.2013.12.009 · Cited by 314
Ribosome biogenesis in disease: new players and therapeutic targets
Jiao, L., Liu, Y., Yu, X.-Y., Pan, X., Zhang, Y., Tu, J., Song, Y.-H., & Li, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01285-4 · Cited by 313
Erratum: New frontiers in translational control of the cancer genome
Truitt, M. L., & Ruggero, D. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.30 · Cited by 303
Ribosome Biogenesis: A Central Player in Cancer Metastasis and Therapeutic Resistance
Elhamamsy, A. R., Metge, B. J., Alsheikh, H. A., Shevde, L. A., & Samant, R. S. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-4087 · Cited by 300
Nucleolar Stress: hallmarks, sensing mechanism and diseases
Yang, K., Yang, J., & Yi, J. (2018) · Cell Stress · doi:10.15698/cst2018.06.139 · Cited by 283
Nucleolar expansion and elevated protein translation in premature aging
Buchwalter, A., & Hetzer, M. W. (2017) · Nature Communications · doi:10.1038/s41467-017-00322-z · Cited by 263
Recent Progress of Targeted G-Quadruplex-Preferred Ligands Toward Cancer Therapy
Asamitsu, S., Obata, S., Yu, Z., Bando, T., & Sugiyama, H. (2019) · Molecules · doi:10.3390/molecules24030429 · Cited by 275
MTOR inhibitors in cancer therapy
Xie, J., Wang, X., & Proud, C. G. (2016) · F1000Research · doi:10.12688/f1000research.9207.1 · Cited by 266
“Bywater et al . have developed an inhibitor of Pol I, CX-5461 70 , which, when used in combination with everolimus, extended the survival of mice with myc-driven lymphoma 71 .”
MethodDonati, G., Peddigari, S., Mercer, C. A., & Thomas, G. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.05.045 · Cited by 262
Cunningham, J. T., Moreno, M. V., Lodi, A., Ronen, S. M., & Ruggero, D. (2014) · Cell · doi:10.1016/j.cell.2014.03.052 · Cited by 260
The Dual Role of Cellular Senescence in Developing Tumors and Their Response to Cancer Therapy
Schosserer, M., Grillari, J., & Breitenbach, M. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00278 · Cited by 259
mTORC1 signaling controls multiple steps in ribosome biogenesis
Iadevaia, V., Liu, R., & Proud, C. G. (2014) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2014.08.004 · Cited by 248
The Ribosome Biogenesis—Cancer Connection
Penzo, M., Montanaro, L., Treré, D., & Derenzini, M. (2019) · Cells · doi:10.3390/cells8010055 · Cited by 242
“Following this research line, another related compound, the CX-5461 molecule, was proposed as a selective inhibitor of rRNA transcription whose action reduces the binding affinity of the SL1 pre-initiation complex and RNA polymerase I complex to rDNA promoters [57,58].”
BackgroundDynamic alternative DNA structures in biology and disease
Wang, G., & Vasquez, K. M. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-022-00539-9 · Cited by 196
Bruno, P. M., Lu, M., Dennis, K. A., Inam, H., Moore, C. J., Sheehe, J., Elledge, S. J., Hemann, M. T., & Pritchard, J. R. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1921649117 · Cited by 175
Lessard, F., Igelmann, S., Trahan, C., Huot, G., Saint-Germain, E., Mignacca, L., Del Toro, N., Lopes-Paciencia, S., Le Calvé, B., Montero, M., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0127-y · Cited by 174
Oncogene-induced senescence: From biology to therapy
Zhu, H., Blake, S., Kusuma, F. K., Pearson, R. B., Kang, J., & Chan, K. T. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111229 · Cited by 116
Self-citationJung, L. A., Gebhardt, A., Koelmel, W., Ade, C. P., Walz, S., Kuper, J., von Eyss, B., Letschert, S., Redel, C., d'Artista, L., et al. (2017) · Oncogene · doi:10.1038/onc.2016.354 · Cited by 101
Conserved regulators of nucleolar size revealed by global phenotypic analyses
Neumüller, R. A., Gross, T., Samsonova, A. A., Vinayagam, A., Buckner, M., Founk, K., Hu, Y., Sharifpoor, S., Rosebrock, A. P., Andrews, B., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004145 · Cited by 87
Pharmacological reactivation of p53 as a strategy to treat cancer
Zawacka‐Pankau, J., & Selivanova, G. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12336 · Cited by 82
Wall, M., Poortinga, G., Stanley, K. L., Lindemann, R. K., Bots, M., Chan, C. J., Bywater, M. J., Kinross, K. M., Astle, M. V., Waldeck, K., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0404 · Cited by 64
Self-citationSanchez-Casalongue, M. E., Lee, J., Diamond, A., Shuldiner, S., Moir, R. D., & Willis, I. M. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.626523 · Cited by 36
Zillner, K., Komatsu, J., Filarsky, K., Kalepu, R., Bensimon, A., & Németh, A. (2015) · Epigenomics · doi:10.2217/epi.14.93 · Cited by 28
Kasteri, J., Das, D., Zhong, X., Persaud, L., Francis, A., Muharam, H., & Sauane, M. (2018) · Cancers · doi:10.3390/cancers10050133 · Cited by 24
Epigenetics of Ribosomal RNA Genes
Denisenko, O. (2022) · Biochemistry (Moscow) · doi:10.1134/s0006297922140097 · Cited by 10
Early nucleolar disorganization in Dictyostelium cell death
Luciani, M. F., Song, Y., Sahrane, A., Kosta, A., & Golstein, P. (2017) · Cell Death & Disease · doi:10.1038/cddis.2016.444 · Cited by 7
Metadata
- Authors
- Bywater, M. J., Poortinga, G., Sanij, E., Hein, N., Peck, A., Cullinane, C., Wall, M., Cluse, L., Drygin, D., Anderes, K., Huser, N., Proffitt, C., Bliesath, J., Haddach, M., Schwaebe, M. K., Ryckman, D. M., Rice, W. G., Schmitt, C., Lowe, S. W., Johnstone, R. W., Pearson, R. B., McArthur, G. A., & Hannan, R. D.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2012-07
- Volume
- 22
- Issue
- 1
- Pages
- 51-65
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2129104457
- Cited by
- 563
- References
- 38
- FWCI
- 16.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.